779 related articles for article (PubMed ID: 26385087)
1. Janus-kinase-2 relates directly to portal hypertension and to complications in rodent and human cirrhosis.
Klein S; Rick J; Lehmann J; Schierwagen R; Schierwagen IG; Verbeke L; Hittatiya K; Uschner FE; Manekeller S; Strassburg CP; Wagner KU; Sayeski PP; Wolf D; Laleman W; Sauerbruch T; Trebicka J
Gut; 2017 Jan; 66(1):145-155. PubMed ID: 26385087
[TBL] [Abstract][Full Text] [Related]
2. Angiotensin-II type 1 receptor-mediated Janus kinase 2 activation induces liver fibrosis.
Granzow M; Schierwagen R; Klein S; Kowallick B; Huss S; Linhart M; Mazar IG; Görtzen J; Vogt A; Schildberg FA; Gonzalez-Carmona MA; Wojtalla A; Krämer B; Nattermann J; Siegmund SV; Werner N; Fürst DO; Laleman W; Knolle P; Shah VH; Sauerbruch T; Trebicka J
Hepatology; 2014 Jul; 60(1):334-48. PubMed ID: 24619965
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Janus kinase-2 signalling pathway ameliorates portal hypertensive syndrome in partial portal hypertensive and liver cirrhosis rats.
Wang D; Yin J; Dong R; Zhao J; Wang Q; Wang N; Wang S; Du X; Lu J
Dig Liver Dis; 2015 Apr; 47(4):315-23. PubMed ID: 25637451
[TBL] [Abstract][Full Text] [Related]
4. Role of estrogen receptor β selective agonist in ameliorating portal hypertension in rats with CCl4-induced liver cirrhosis.
Zhang CG; Zhang B; Deng WS; Duan M; Chen W; Wu ZY
World J Gastroenterol; 2016 May; 22(18):4484-500. PubMed ID: 27182159
[TBL] [Abstract][Full Text] [Related]
5. Terutroban, a TP-receptor antagonist, reduces portal pressure in cirrhotic rats.
Rosado E; Rodríguez-Vilarrupla A; Gracia-Sancho J; Tripathi D; García-Calderó H; Bosch J; García-Pagán JC
Hepatology; 2013 Oct; 58(4):1424-35. PubMed ID: 23703868
[TBL] [Abstract][Full Text] [Related]
6. Intrahepatic upregulation of RhoA and Rho-kinase signalling contributes to increased hepatic vascular resistance in rats with secondary biliary cirrhosis.
Zhou Q; Hennenberg M; Trebicka J; Jochem K; Leifeld L; Biecker E; Sauerbruch T; Heller J
Gut; 2006 Sep; 55(9):1296-305. PubMed ID: 16492715
[TBL] [Abstract][Full Text] [Related]
7. AMPK agonist AICAR ameliorates portal hypertension and liver cirrhosis via NO pathway in the BDL rat model.
Hu L; Su L; Dong Z; Wu Y; Lv Y; George J; Wang J
J Mol Med (Berl); 2019 Mar; 97(3):423-434. PubMed ID: 30721324
[TBL] [Abstract][Full Text] [Related]
8. TGR(mREN2)27 rats develop non-alcoholic fatty liver disease-associated portal hypertension responsive to modulations of Janus-kinase 2 and Mas receptor.
Klein S; Kleine CE; Pieper A; Granzow M; Gautsch S; Himmit M; Kahrmann K; Schierwagen R; Uschner FE; Magdaleno F; Naoum ME; Kristiansen G; Walther T; Bader M; Sauerbruch T; Trebicka J
Sci Rep; 2019 Aug; 9(1):11598. PubMed ID: 31406138
[TBL] [Abstract][Full Text] [Related]
9. Sodium ferulate lowers portal pressure in rats with secondary biliary cirrhosis through the RhoA/Rho-kinase signaling pathway: a preliminary study.
Wei L; Yang J; Wang M; Xu SN; Liang HM; Zhou Q
Int J Mol Med; 2014 Nov; 34(5):1257-67. PubMed ID: 25174394
[TBL] [Abstract][Full Text] [Related]
10. HSC-specific inhibition of Rho-kinase reduces portal pressure in cirrhotic rats without major systemic effects.
Klein S; Van Beuge MM; Granzow M; Beljaars L; Schierwagen R; Kilic S; Heidari I; Huss S; Sauerbruch T; Poelstra K; Trebicka J
J Hepatol; 2012 Dec; 57(6):1220-7. PubMed ID: 22878469
[TBL] [Abstract][Full Text] [Related]
11. Sodium Ferulate Reduces Portal Pressure Through Inhibition of RhoA/Rho-Kinase and Activation of Endothelial Nitric Oxide Synthase in Cirrhotic Rats.
Liu J; Peng L; Yang J; Wang M; Xu S; Liu J; Han P; He J; Tian D; Zhou Q
Dig Dis Sci; 2015 Jul; 60(7):2019-29. PubMed ID: 25724163
[TBL] [Abstract][Full Text] [Related]
12. Combined administration of propranolol + AG490 offers better effects on portal hypertensive rats with cirrhosis.
Wang D; Wang Q; Yin J; Dong R; Wang Q; Du X; Lu J
J Gastroenterol Hepatol; 2016 May; 31(5):1037-44. PubMed ID: 26487394
[TBL] [Abstract][Full Text] [Related]
13. Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase.
Trebicka J; Hennenberg M; Laleman W; Shelest N; Biecker E; Schepke M; Nevens F; Sauerbruch T; Heller J
Hepatology; 2007 Jul; 46(1):242-53. PubMed ID: 17596891
[TBL] [Abstract][Full Text] [Related]
14. Rho-kinase inhibitor coupled to peptide-modified albumin carrier reduces portal pressure and increases renal perfusion in cirrhotic rats.
Klein S; Frohn F; Magdaleno F; Reker-Smit C; Schierwagen R; Schierwagen I; Uschner FE; van Dijk F; Fürst DO; Djudjaj S; Boor P; Poelstra K; Beljaars L; Trebicka J
Sci Rep; 2019 Feb; 9(1):2256. PubMed ID: 30783172
[TBL] [Abstract][Full Text] [Related]
15. Statins activate the canonical hedgehog-signaling and aggravate non-cirrhotic portal hypertension, but inhibit the non-canonical hedgehog signaling and cirrhotic portal hypertension.
Uschner FE; Ranabhat G; Choi SS; Granzow M; Klein S; Schierwagen R; Raskopf E; Gautsch S; van der Ven PF; Fürst DO; Strassburg CP; Sauerbruch T; Diehl AM; Trebicka J
Sci Rep; 2015 Sep; 5():14573. PubMed ID: 26412302
[TBL] [Abstract][Full Text] [Related]
16. Panax notoginseng saponins ameliorates experimental hepatic fibrosis and hepatic stellate cell proliferation by inhibiting the Jak2/ Stat3 pathways.
Hui J; Gao J; Wang Y; Zhang J; Han Y; Wei L; Liu Xiaochuang ; Wu J
J Tradit Chin Med; 2016 Apr; 36(2):217-24. PubMed ID: 27400477
[TBL] [Abstract][Full Text] [Related]
17. Soluble guanylyl cyclase stimulation and phosphodiesterase-5 inhibition improve portal hypertension and reduce liver fibrosis in bile duct-ligated rats.
Brusilovskaya K; Königshofer P; Lampach D; Szodl A; Supper P; Bauer D; Beer A; Stift J; Timelthaler G; Oberhuber G; Podesser BK; Seif M; Zinober K; Rohr-Udilova N; Trauner M; Reiberger T; Schwabl P
United European Gastroenterol J; 2020 Dec; 8(10):1174-1185. PubMed ID: 32878579
[TBL] [Abstract][Full Text] [Related]
18. Role of beta3-adrenoceptors for intrahepatic resistance and portal hypertension in liver cirrhosis.
Trebicka J; Hennenberg M; Schulze Pröbsting A; Laleman W; Klein S; Granzow M; Nevens F; Zaagsma J; Heller J; Sauerbruch T
Hepatology; 2009 Dec; 50(6):1924-35. PubMed ID: 19842096
[TBL] [Abstract][Full Text] [Related]
19. Expression of vasoactive proteins in gastric antral mucosa reflects vascular dysfunction in patients with cirrhosis and portal hypertension.
Trebicka J; Wix C; von Heydebrand M; Hittatiya K; Reiberger T; Klein S; Schierwagen R; Kristiansen G; Peck-Radosavljevic M; Fischer HP; Møller S; Bendtsen F; Krag A; Sauerbruch T
Liver Int; 2015 Apr; 35(4):1393-402. PubMed ID: 24912856
[TBL] [Abstract][Full Text] [Related]
20. Hemodynamic Effects of the Non-Peptidic Angiotensin-(1-7) Agonist AVE0991 in Liver Cirrhosis.
Klein S; Herath CB; Schierwagen R; Grace J; Haltenhof T; Uschner FE; Strassburg CP; Sauerbruch T; Walther T; Angus PW; Trebicka J
PLoS One; 2015; 10(9):e0138732. PubMed ID: 26406236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
